Pancreatic Cancer News

Sutent® Provides Significant Benefit for Advanced Pancreatic Islet Cell Tumors: Clinical Trial Stopped Early (March 31, 2009)

Sutent® (sunitinib malate) has been shown to significantly increase progression-free survival in patients with advanced pancreatic islet cell tumors, leading Pfizer Inc. to halt their Phase III trial early.[1] Sutent is an oral targeted agent that works... Continue Reading

Blood Type Linked to Risk of Pancreatic Cancer (March 31, 2009)

Individuals with A, AB, or B blood types may have a higher risk of developing pancreatic cancer, according to the results of a study published in the Journal of the National Cancer Institute.[1] The pancreas is an organ that is surrounded by the stomach,... Continue Reading

Obesity Worsens Outcomes After Surgery for Pancreatic Cancer (March 31, 2009)

According to the results of a study published in the Archives of Surgery, pancreatic caner patients with a body mass index (BMI) greater than 35 have a greater risk of recurrence and worse survival after surgery than patients with a lower BMI. Obesity... Continue Reading

Three-drug Combination Increases Rates of Larynx Preservation (March 31, 2009)

Among patients with locally advanced cancer of the larynx or hypopharynx, induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (5-FU) resulted in higher rates of larynx preservation than induction chemotherapy with only cisplatin and 5-FU.... Continue Reading

Alcohol Modestly Increases Risk of Pancreatic Cancer (March 5, 2009)

Alcohol Modestly Increases Risk of Pancreatic Cancer According to a combined analysis of 14 previous studies, individuals who consume more than about 2½ drinks per day are 22% more likely to develop pancreatic cancer than nondrinkers. These results were... Continue Reading

Neoadjuvant Radiation Improves Survival in Pancreatic Cancer (December 5, 2008)

Neoadjuvant Radiation Improves Survival in Pancreatic Cancer Preoperative radiation nearly doubles the survival rate for patients with operable pancreatic cancer, according to the results of a study published in the November 15, 2008 issue of the International... Continue Reading

EndoTAG™-1 Shows Promise in Treatment of Pancreatic Cancer (September 17, 2008)

EndoTAG™-1 Shows Promise in Treatment of Pancreatic Cancer According to the results of a Phase II clinical trial, the addition of the investigational drug EndoTAG™-1 to chemotherapy with Gemzar® (gemcitabine) may improve survival among patients with... Continue Reading

EndoTAG™-1 Shows Promise in Treatment of Pancreatic Cancer (September 17, 2008)

Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers (July 23, 2008)

Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers Researchers recommend that at least 15 lymph nodes be removed and examined in patients with early gastric or pancreatic cancers. These results were recently published in... Continue Reading

Gemzar® Improves Survival with Early Pancreatic Cancer (June 10, 2008)

Gemzar® Improves Survival with Early Pancreatic Cancer Adjuvant (post-surgery) chemotherapy with Gemzar® (gemcitabine) significantly improves disease-free and overall survival among patients with early pancreatic cancer. These findings were presented... Continue Reading